{
  "title": "Health Issues in First Episode of Psychosis",
  "itunes:title": "Health Issues in First Episode of Psychosis",
  "pubDate": "Mon, 02 May 2022 16:00:22 +0000",
  "guid": "e6af399e-2cc8-4a95-88bc-d4da04a3c3a2",
  "link": "https://psychopharmacology.libsyn.com/health-issues-in-first-episode-of-psychosis",
  "itunes:image": "",
  "description": "<p>Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness?</p> <p>This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early metabolic changes. </p> <p>Faculty: Stephen Marder, M.D. <br /> Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><strong><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156\"> Learn more about our memberships here</a></strong></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156\"> <strong>Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/health-concerns-for-first-episode-patients-2611-5115?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156\"> <strong>Health Concerns for First-Episode Patients</strong></a></li> </ul> <p> </p>",
  "content:encoded": "<p>Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness?</p> <p>This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early metabolic changes. </p> <p>Faculty: Stephen Marder, M.D.  Hosts: Jessica Diaz, M.D., Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156\"> Learn more about our memberships here</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/assessment-and-management-of-first-episode-of-psychosis-2611?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156\"> Earn 0.75 CMEs: Assessment and Management of First Episode of Psychosis</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/health-concerns-for-first-episode-patients-2611-5115?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC156\"> Health Concerns for First-Episode Patients</a></li> </ul> <p> </p>",
  "enclosure": "",
  "itunes:duration": "09:43",
  "itunes:explicit": false,
  "itunes:keywords": "",
  "itunes:subtitle": "Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness? This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the...",
  "itunes:episodeType": "full"
}